financetom
Business
financetom
/
Business
/
Live Nation Faces UK, EU Probes Over Dynamic Pricing After Surge for Oasis Tickets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Live Nation Faces UK, EU Probes Over Dynamic Pricing After Surge for Oasis Tickets
Sep 4, 2024 1:04 AM

04:02 PM EDT, 09/03/2024 (MT Newswires) -- Live Nation (LYV) and its Tickermaster unit will soon be the subject of regulatory reviews in the UK and the European Union following a surge in the price of tickets for an upcoming reunion tour of English band Oasis due to the company's use of dynamic pricing, according to media reports on Tuesday.

The UK's Competition and Markets Authority said Monday it was launching a review into the company's dynamic pricing model, which automatically adjusts the cost of admission to events based on customer demand. Tickets originally priced at 135 British pounds ($176.79) jumped to around 350 pounds with buyers often not finding out the sale price they paid until checking out, the reports said.

"Consumer protection law requires businesses to be fair and transparent in their dealing with consumers," the agency said in a statement distributed to media outlets. "Businesses must give clear and accurate information about the price people have to pay."

A spokesperson for the European Commission told the Guardian some of its regulator bodies were also looking into dynamic pricing to determine whether new laws are needed to better regulate the practice.

Live Nation did not immediately respond to a message Tuesday from MT Newswires seeking comment. The European Commission and the Competition and Markets Authority in the UK also did not return messages to MT Newswires.

Price: 95.21, Change: -2.46, Percent Change: -2.52

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Meta Platforms to use Reuters news content in AI chatbot
Meta Platforms to use Reuters news content in AI chatbot
Nov 3, 2024
(Reuters) - Meta Platforms said on Friday its artificial intelligence chatbot will use Reuters content to answer user questions in real time about news and current events, the latest AI tie-up between a big technology company and a news publisher. Neither Meta nor Reuters-parent Thomson Reuters disclosed the financial details of the partnership. The arrangement would be its first news...
Builders FirstSource Likely to Expand Earnings Faster Than Expected, UBS Says
Builders FirstSource Likely to Expand Earnings Faster Than Expected, UBS Says
Nov 3, 2024
12:46 PM EDT, 10/25/2024 (MT Newswires) -- Builders FirstSource ( BLDR ) is likely to expand its earnings faster than expected, driving potential upside to its share price, UBS Securities said Friday in a note initiating coverage of the company. The firm said it was forecasting a roughly 13% adjusted earnings per share compound annual growth rate through 2026, well...
Thiel's Palantir dumped by Norwegian investor over work for Israel
Thiel's Palantir dumped by Norwegian investor over work for Israel
Nov 3, 2024
LONDON/OSLO (Reuters) - One of the Nordic region's largest investors has sold its holdings in Palantir Technologies ( PLTR ) because of concerns that the U.S. data firm's work for Israel might put the asset manager at risk of violating international humanitarian law and human rights.  Storebrand Asset Management disclosed this week that it had excluded Palantir Technologies Inc. (...
Tyra Biosciences Shares Retreat After Gains Following Positive Clinical Trial Results for TYRA-300
Tyra Biosciences Shares Retreat After Gains Following Positive Clinical Trial Results for TYRA-300
Nov 3, 2024
12:39 PM EDT, 10/25/2024 (MT Newswires) -- Tyra Biosciences ( TYRA ) shares were down more than 21% in recent Friday trading, reversing earlier gains spurred by the company's disclosure of positive clinical proof-of-concept data for TYRA-300. The company said Thursday that preliminary data from its ongoing SURF301 phase 1/2 study showed TYRA-300, an investigational oral fibroblast growth factor receptor-selective...
Copyright 2023-2026 - www.financetom.com All Rights Reserved